MURA - Multiplikator P/S Mural Bio
Mural Oncology plc develops unique immunotherapeutic drugs, whose patent protection allows for high treatment pricing. However, the company faces risks of clinical trial failures and significant pressure from industry behemoths. Currently, the business is systematically spending the capital received upon spin-off on research. The price-to-sales ratio dynamics on the GURU.Markets platform clearly demonstrate this process, where the value captures this metric.
Mural Oncology PLC (MURA) - rincian metrik lan laporan keuangan
- rega pasar lan target rega analis:
- statistik kapitalisasi pasar:
- data ekuitas miturut neraca:
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Mural Oncology plc|MURA - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Mural Oncology PLC|MURA - Utang perusahaan|Utang-utang marang nilai buku Mural Oncology|MURA - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Mural Oncology|Indikator likuiditas cepet muraloncology.com
- informasi bathi lan kelipatan valuasi:
MURA - Bathi resik perusahaan|Bathi resik sing dikarepake Mural Oncology plc|MURA - Rasio rega marang bathi|Rega marang bathi mangsa ngarep Mural Oncology PLC|MURA - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan MURA|MURA - Bathi operasional EBITDA|Bathi resik saben saham sajroning taun lumaku Mural Oncology|MURA - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan muraloncology.com|MURA - Wutah bathi resik saben saham ing taun iki|Dinamika bathi saben saham sing diarepake ing taun ngarep Mural Oncology plc
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:MURA - Mural Oncology plc
The biopharmaceutical sector is sensitive to regulatory shocks and environmental safety costs at Mural Oncology plc (MURA). The implementation of energy-saving measures and hazardous emission filtration systems creates a foundation for long-term business sustainability. The P/S ratio correlates market capitalization with annual revenue, determining the cost of each unit of sales. By analyzing current P/S dynamics, an investor can assess the degree of asset overvaluation and the risk of a price correction.
Pesaing Mural Oncology plc
ONC - Rega marang dodolan|Multiplikator P/S HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Rega marang dodolan|ascentage.com - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan CGON (cgoncology.com)|URGN: Multiplikator P/S|Bicara Therapeutics Inc (BCAX) - Multiplikator P/S|Rasio rega marang pendapatan personalis.com|Kapitalisasi marang pendapatan Erasca Corp (ERAS)|Kapitalisasi marang pendapatan DCTH (Delcath)|Koefisien rega marang pendapatan Y-mAbs Therapeutics, Inc.|Multiplikator P/S AURA (Aura Biosciences Inc)|Rasio kapitalisasi pasar marang pendapatan CADL|ARAY: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan CTOR|Rasio rega marang pendapatan TuHURA Biosciences Inc.|TARA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Fate Therapeutics (FATE)|Koefisien rega marang pendapatan Aadi Bioscience|Rasio rega marang pendapatan TScan Therapeutics Inc TCRX|CSBR: Rasio kapitalisasi marang pendapatan|XBIT: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CVM (cel-sci.com)|OSTX: Multiplikator P/S|Rega marang dodolan Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ANL (Adlai Nortye)|Rasio rega marang pendapatan Veru Pharma (VERU)|Multiplikator P/S Tempest Tx (TPST)|Rasio rega marang pendapatan xiliotx.com XLO|Enochian BioSciences - Rasio rega marang pendapatan|KAPA - Rasio rega marang pendapatan|OnKure Therapeutics (OKUR) - Kapitalisasi marang pendapatan|GDTC: Multiplikator P/S|Rega marang dodolan Curis Corp (CRIS)|APLM (apollomicsinc.com) - Multiplikator P/S|Kapitalisasi marang pendapatan Tharimmune Corp (THAR)|Multiplikator P/S ADVB|GNPX - Rega marang dodolan|Rasio rega marang pendapatan calidibio.com CLDI|SBFM - Kapitalisasi marang pendapatan|XBIO - Rasio rega marang pendapatan|SLRX: Rasio rega marang pendapatan|Purple Biotech (PPBT) - Rasio rega marang pendapatan|AON - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BGNE|Multiplikator P/S Checkpoint Therapeutics Inc.|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan iCAD ICAD|Multiplikator P/S IKNA (Ikena Oncology, Inc.)|Rasio kapitalisasi pasar marang pendapatan NTBL|Viracta Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalisasi marang pendapatan|Kapitalisasi marang pendapatan Ascentage Pharma Group Ltd
